Patient Square Capital’s Terns Pharmaceuticals TERN Stock Holding History

Patient Square Capital’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-320,000	Closed	-$12.9M	–	35
2025 Q4	$12.9M	Buy	+320,000	New	+$7.4M	2.77%	9

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Patient Square Capital's TERN Position: Q1 2026 in Review

Patient Square Capital sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 320,000 shares — an estimated $12.9M sold.

Patient Square Capital first reported a position in TERN in Q4 2025 and held it in 1 quarter. The position peaked at $12.9M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

Patient Square Capital reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Patient Square Capital sold 320,000 Terns Pharmaceuticals shares in Q1 2026, an estimated $12.9M.
Patient Square Capital first reported a position in Terns Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Patient Square Capital's Terns Pharmaceuticals position peaked at $12.9M in Q4 2025.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Patient Square Capital's 13F filing for Q1 2026, filed 15 May 2026.